# Revelation Biosciences, Inc.: Form 10-Q/A for the period ended Jun 30, 2024

- Company: [Revelation Biosciences, Inc.](/companies/revb.md) (CIK 1810560)
- Form: 10-Q/A
- Filed: 2024-09-23
- Accepted by EDGAR: Sep 23, 2024, 16:57 ET
- Period: 2024-06-30
- Accession: 0000950170-24-108797
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024108797/revb-20240630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1810560/000095017024108797/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2024-04-01 to 2024-06-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2024-01-01 to 2024-06-30 | $2.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$4.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-04-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$8.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$11.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-04-01 to 2024-06-30 | −$5.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-01-01 to 2024-06-30 | −$8.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-04-01 to 2024-06-30 | −$5.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-01-01 to 2024-06-30 | −$8.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-04-01 to 2024-06-30 | 1,635,234 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-01-01 to 2024-06-30 | 1,362,534 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$5.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-01-01 to 2024-06-30 | $19.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-06-30 | $12.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-06-30 | $12.2m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $12.3m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $11.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $11.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-06-30 | $1.1m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1810560/000095017024108797/revb-20240630.htm

Filed Sep 23, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-108797. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.